Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial
暂无分享,去创建一个
B. Pégourié | S. Leyvraz | P. Moreau | H. Avet-Loiseau | G. Marit | C. Mathiot | T. Facon | C. Doyen | J. Harousseau | M. Attal | C. Berthou | A. Stoppa | P. Lenain | C. Hulin | D. Caillot | L. Benboubker | M. Michallet | H. Maisonneuve | P. Casassus
[1] M. Mohty,et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Baccarani,et al. A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD. , 2009 .
[3] D. Esseltine,et al. High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. , 2009 .
[4] K. Anderson,et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. , 2009, Blood.
[5] David E. Irwin,et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. , 2009, Blood.
[6] B. Barlogie,et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) , 2009, Leukemia.
[7] D. Esseltine,et al. Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up , 2008, British journal of haematology.
[8] A. Bhandoola,et al. The earliest thymic progenitors for T cells possess myeloid lineage potential , 2008, Nature.
[9] S. Paolini,et al. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. , 2008, Clinical advances in hematology & oncology : H&O.
[10] A. Oriol,et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Arceci,et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Pégourié,et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. , 2006, Haematologica.
[13] S. Jagannath,et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma , 2005, British journal of haematology.